Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 11/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6607173 | 0.87 | CASP3 (0.52) | CASP3CA2CA1ALDH1A1 | |
| SCHEMBL6606162 | 0.86 | CASP3 (0.52) | CASP3CA2CA1 | |
| SCHEMBL6610883 | 0.85 | HPGDS (0.53) | CASP3CA2CA1 | |
| SCHEMBL6607828 | 0.85 | CASP3 (0.53) | CASP3CA2CA1GAAALDH1A1 | |
| SCHEMBL6607193 | 0.85 | GRN (0.55) | CASP3 | |
| SCHEMBL6609614 | 0.85 | GRN (0.56) | CASP3HTTCA2CA1KDM4E | |
| SCHEMBL11529390 | 0.84 | CA2 (0.64) | CASP3HTTCA2CA1KDM4E | |
| SCHEMBL6607169 | 0.84 | CA2 (0.47) | CASP3CA2CA1LMNA | |
| SCHEMBL6608901 | 0.83 | CASP3 (0.53) | CASP3 | |
| SCHEMBL6606242 | 0.82 | MEN1 (0.49) | CASP3CA2CA1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163208-B1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6632962-B2 | N-(2-carboxy-1-haloacetylethyl)arylamide derivatives as inhibitors of caspase and cellular apoptosis. | VERTEX PHARMACEUTICALS INCORPORATED | 2003-10-14 | — | — | US | disclosed |
| US-20020132833-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-09-19 | — | — | US | disclosed |
| EP-1163208-A4 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2002-07-03 | — | — | EP | disclosed |
| EP-1163208-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2001010383-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132833-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP7 | CASP3 2/4885HTT 3553/4885CA2 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.